@article{RN631,

title = {Anemia diagnosis and therapy in malignant diseases: implementation of guidelines\textemdasha representative study},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann and Markus Detzner},

url = {https://doi.org/10.1007/s00520-023-08267-4},

doi = {10.1007/s00520-023-08267-4},

issn = {1433-7339},

year  = {2024},

date = {2024-01-19},

urldate = {2024-01-19},

journal = {Supportive Care in Cancer},

volume = {32},

number = {2},

pages = {113},

abstract = {Purpose: Anemia in cancer should be diagnosed and treated according to guideline recommendations. The implementation of ESMO and German guidelines and their effect on anemia correction was analyzed. 

Methods: This retrospective epidemiological study, representative for Germany, analyzed data on anemia management of cancer patients with anemia ≥ grade 2. The Guideline Adherence Score (GLAD) for diagnosis (GLAD-D) and therapy (GLAD-T) was defined as follows: 2 points for complete, 1 point for partial, 0 point for no adherence. 

Results: Data were analyzed for 1046 patients. Hb levels at diagnosis of anemia were 8-10 g/dL in 899 (85.9%) patients, 7-8 g/dL in 92 (8.7%), and \< 7 g/dL (5.0%) in 52. Transferrin saturation was determined in 19% of patients. Four hundred fifty-six patients received RBC (43.6%), 198 (18.9%) iron replacement, 106 (10.1%) ESA, and 60 (5.7%) vitamin B12 replacement. 60.6% of patients receiving iron replacement were treated intravenously and 39.4% were treated orally. Two hundred eighty-eight (36.6%) of 785 patients receiving transfusions had no guideline-directed indication. GLAD-D was 2 in 310 patients (29.6%), 1 in 168 (16.1%), and 0 in 568 (54.3%). GLAD-T was 2 in 270 patients (25.8%), 1 in 320 patients (30.6%), and 0 in 456 patients (43.6%). Higher GLAD-D significantly correlated with higher GLAD-T (τB = 0.176, p \< 0.001). GLAD-T 2 was significantly associated with greater Hb increase than GLAD-T 0/1 (p \< 0.001) at 28 days (10.2 vs. 9.7 g/ dL) and at 2 months (10.4 vs. 9.9 g/dL). 

Conclusions: Anemia assessment is inadequate, transfusion rates too high, and iron and ESA therapy too infrequent.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN630,

title = {Qualit\"{a}tssicherung zur Diagnose und Therapie von Harnblasenkarzinomen 2023 (QS Harnblase)},

author = {Carsten-Henning Ohlmann and Peter Hammerer and Viktor Gr\"{u}nwald and G\"{u}nter Niegisch and Markus Kerkmann and Laura Holtmann and Heidrun Rexer},

url = {https://doi.org/10.1007/s12312-023-01273-x

https://www.mmf-research.de/forum-qs-harnblase-2023/},

doi = {10.1007/s12312-023-01273-x},

issn = {2190-9784},

year  = {2023},

date = {2023-12-15},

urldate = {2023-12-15},

journal = {Forum},

abstract = {In Deutschland erkranken j\"{a}hrlich fast 18.000 Menschen neu an Blasenkrebs; M\"{a}nner sind etwa dreimal so h\"{a}ufig betroffen wie Frauen. Damit ist das Harnblasenkarzinom die vierth\"{a}ufigste b\"{o}sartige Erkrankung bei M\"{a}nnern und die vierzehnth\"{a}ufigste bei Frauen. Um detaillierte Einblicke in den klinischen Alltag und die Umsetzung der Therapieempfehlungen der Leitlinien in Deutschland zu erhalten sowie m\"{o}gliche regionale und strukturelle Unterschiede zu identifizieren, wurde im Jahr 2020 von den Arbeitsgemeinschaften Urologische Onkologie (AUO) und Internistische Onkologie (AIO) in der Deutschen Krebsgesellschaft (DKG) die Qualit\"{a}tssicherungsinitiative Harnblase ins Leben gerufen, die auch von der Interdisziplin\"{a}ren Arbeitsgruppe BlasenCarcinom (IABC) unterst\"{u}tzt wird. Ziel der Initiative ist es, in regelm\"{a}\ssigen Abst\"{a}nden repr\"{a}sentativ die Qualit\"{a}t der Therapie beim Harnblasenkarzinomin Deutschland zu erfassen, zu analysieren und daraus Erkenntnisse zu gewinnen, die in Ma\ssnahmen zur Qualit\"{a}tssteigerungumgesetzt werden k\"{o}nnen.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN617,

title = {QS ENDO Pilot \textendash A Study by the Stiftung Endometrioseforschung (SEF) on the Quality of Care Provided to Patients with Endometriosis in Certified Endometriosis Centers in the DACH Region},

author = {Ivo Meinhold-Heerlein and Magdalena Zeppernick and Monika Martina W\"{o}lfler and Elisabeth Janschek and Sebastian Bornemann and Laura Holtmann and Frank Oehmke and Darius Salehin and Chi Mi Scheible and Iris Brandes and Sigrid Vingerhagen-Pethick and Claus-Peter Cornelius and Alexander Boosz and Bernhard Kr\"{a}mer and Martin Sillem and B\"{u}hler† Klaus and J\"{o}rg Keckstein and Karl-Werner Schweppe and Felix Zeppernick and A. G. Q. S. Endo of the Stiftung Endometrioseforschung the},

url = {http://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-2061-6845},

doi = {10.1055/a-2061-6845},

issn = {0016-5751 1438-8804},

year  = {2023},

date = {2023-05-25},

urldate = {2023-05-25},

journal = {Geburtshilfe Frauenheilkd},

number = {83},

pages = {835-842},

abstract = {Introduction: Endometriosis significantly reduces patientsʼ quality of life and is additionally a burden on healthcare and social security systems. There are currently no quality indicators for the treatment of endometriosis. The care of patients with endometriosis must be considered inadequate. QS ENDO aims to record the quality of care available in the DACH region and to introduce quality indicators for the diagnosis and treatment of endometriosis as part of providing quality assurance in endometriosis care. The first phase, QS ENDO Real, recorded the reality of current care using a questionnaire. The second phase, QS ENDO Pilot, investigated the treatment of 435 patients who underwent surgical treatment within a defined one month period in certified endometriosis centers.



Material and Methods: An online tool was used to gather information about 9 points which covered both prior patient history and the process of clinical diagnosis. Surgery reports were reviewed to obtain information about the surgical approach, the investigated sites, findings of any histological examinations, the use of classification systems, and information about resection status.



Results: 85.3% of patients were asked all 4 questions about their prior medical history. All 5 diagnostic steps were carried out in 34.5% of patients. The 3 areas needed to describe potential sites of disease were recorded in 67.1% of patients. Samples for histological examination were taken in 84.1% of patients. The endometriosis stage was classified in 94.7% of surgeries. A combination of the rASRM and the ENZIAN classifications, which is needed for complex cases, was used in 46.1% of patients. Complete resection was achieved in 81.6% of surgical procedures.



Conclusion For the first time, the quality of care in certified endometriosis centers has been recorded using QS ENDO Pilot. Despite the high certification standards, a substantial number of required indicators were omitted.



Key words

endometriosis - quality assurance - reality of current care - healthcare research},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Wimbergerijgc-2022-004233,

title = {Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group},

author = {Pauline Wimberger and Jacobus Pfisterer and Andreas Bois and Felix Hilpert and Markus Kerkmann and Jalid Sehouli and Sven Mahner and Nikolaus Gregorio and Lars Hanker and Florian Heitz and Frederik Marm\'{e} and Linn Woelber and Laura Holtmann and Gabriele Elser and Philipp Harter},

url = {https://ijgc.bmj.com/content/early/2023/03/30/ijgc-2022-004233},

doi = {10.1136/ijgc-2022-004233},

issn = {1048-891X},

year  = {2023},

date = {2023-03-31},

urldate = {2023-03-31},

journal = {International Journal of Gynecologic Cancer},

volume = {33},

number = {1083-1089},

publisher = {BMJ Specialist Journals},

abstract = {Objective The quality assurance program for ovarian cancer (QS-OVAR) evaluates the implementation of treatment standards and impact on survival for International Federation of Gynecology and Obstetrics (FIGO) stage I ovarian cancer.Methods Patients with a first diagnosis of ovarian cancer, diagnosed in the third quarter of 2004, 2008, 2012, and 2016, were documented. Surgical quality was categorized as optimal (maximum one surgical item missing) versus suboptimal (\>=2 surgical items missing). Chemotherapy was defined as optimal according to national guidelines. Treatment quality was classified into four categories: surgery and chemotherapy were optimal, optimal surgery and suboptimal chemotherapy, suboptimal surgery and optimal chemotherapy, and surgery and chemotherapy were suboptimal.Results In total, 19.9% (n=700) of ovarian cancer patients were diagnosed with FIGO stage I. Median age was 60 years (range 18\textendash96), 47.1% had FIGO stage IA and 47.9% had stage IC, with 37.1% high grade serous histology. Optimal surgical quality increased over time from 19.9% to 54.1%. The optimal surgery population increased from 42.2% to 70.9%. Disease free survival improved significantly in the optimal surgery population (84% after 48 months vs 71% in the suboptimal surgery population). Overall survival increased with 91% after 48 months in the optimal surgery population versus 76% in the suboptimal surgery population. In total, 20.7% of patients were undertreated concerning systemic treatment and 1% overtreated. Optimal chemotherapy standard was administered increasingly over time (71.4\textendash80.8%). Disease free survival and overall survival were prolonged with adjuvant chemotherapy. The optimal surgery/chemotherapy subgroup increased from 37.9% to 54.1% with significantly longer disease free survival and overall survival (overall survival at 48 months: optimal surgery and chemotherapy 93%; suboptimal surgery and chemotherapy 68%).Conclusion Although QS-OVAR data showed that the quality of therapy has improved over the years, not all surgical standards were met in nearly 50% of patients. The steady increase in the optimal surgery and chemotherapy collective is an important tool for improvement of prognosis of ovarian cancer patients.All data relevant to the study are included in the article or uploaded as supplementary information.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN532,

title = {Real World Daten zu Therapie und Krankheitsverlauf von Patientinnen mit erstem Rezidiv eines Ovarialkarzinoms in Deutschland (QS Ovar der AGO Studiengruppe)},

author = {B. Schmalfeldt and A. Bois and J. Pfisterer and F. Hilpert and M. Kerkmann and J. Sehouli and S. Mahner and N. Gregorio and L. Hanker and F. Heitz and F. Marm\'{e} and L. W\"{o}lber and L. Holtmann and A. Kr\"{u}ger and P. Harter},

url = {https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1757039},

doi = {10.1055/s-0042-1757039},

issn = {0016-5751},

year  = {2022},

date = {2022-10-11},

urldate = {2022-10-11},

journal = {Geburtshilfe Frauenheilkd},

volume = {82},

number = {10},

pages = {319},

abstract = {Einleitung Deutschlandweite Daten zur Therapiequalit\"{a}t und zum Krankheitsverlauf von Patientinnen mit Rezidiv eines Ovarialkarzinoms gibt es bisher nicht.



Methodik Alle Krankenh\"{a}user in Deutschland, die Patientinnen mit Ovarialkarzinom behandeln, wurden angeschrieben, bei Patientinnen mit Erstdiagnose im dritten Quartal 2012 und 2016 Tumordaten, Therapie und Verlauf zu dokumentieren. In der vorliegenden Analyse wurden Therapie und Verlauf nach erstem Rezidiv ausgewertet.



Ergebnisse 840 Patientinnen mit Rezidiv wurden eingeschlossen. 754 (89,8%) wiesen eine high grade Histologie auf. Das mediane therapiefreie Intervall nach Abschluss der platinbasierten Erstlinientherapie betrug 12,4 Monate (Spannweite 0-55,7). Bei 144 (17,2%) wurde eine erneute zytoreduktive Chirurgie durchgef\"{u}hrt. Makroskopische Tumorfreiheit wurde bei 48,6% erreicht. Das PFS und OS dieser Patienten lag bei 18,3 und 31,5 Monaten. 599 Patientinnen erhielten eine Rezidivtherapie; bei 445 war diese platinbasiert. Das mediane PFS von Patientinnen mit platinfreier Therapie betrug 4,6 gegen\"{u}ber 11,5 Monaten bei platinbasierter Therapie (HR 0.37, 95%-CI 0.30-0.45, p\<0.001), das OS 9,4 versus 20,8 Monate (HR 0.46, 95%-CI 0.37-0.57, p\<0.001). Nur 4,7% der f\"{u}r eine platinhaltige Rezidivtherapie geeigneten Patientinnen waren unter dieser progredient. 120 Patienten f\"{u}hrten eine Erhaltungstherapie mit einem PARP Inhibitor durch. PFS und OS dieser Patientinnen lag bei 15,4 and 33,4 Monaten.



Schlussfolgerung Der Gro\ssteil der Patientinnen mit erstem Rezidiv erhielt eine erneute platinhaltige Therapie und nur sehr wenige davon waren sekund\"{a}r platinresistent. Das \"{U}berleben nach Rezidivoperation als auch mit PARP Inhibitor Erhaltungstherapie war besser als nach platinbasierter Therapie alleine.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN531,

title = {Steigerung der Therapiequalit\"{a}t beim fr\"{u}hen Ovarialkarzinom: Ergebnisse der QS-Ovar},

author = {P. Wimberger and J. Pfisterer and A. Bois and F. Hilpert and M. Kerkmann and J. Sehouli and S. Mahner and N. Gregorio and L. Hanker and F. Heitz and F. Marm\'{e} and L. W\"{o}lber and L. Holtmann and G. Elser and P. Harter},

doi = {10.1055/s-0042-1757107},

issn = {0016-5751},

year  = {2022},

date = {2022-10-11},

urldate = {2022-10-11},

journal = {Geburtshilfe Frauenheilkd},

volume = {82},

number = {10},

pages = {387},

abstract = { Zielsetzung QS-Ovar dokumentierte von 2004 bis 2016 alle im 3. Quartal erstdiagnostizierten Ovarialkarzinome (OC). Diese repr\"{a}sentative Datenerhebung soll Umsetzung von Therapiestandards und Auswirkungen auf das \"{U}berleben f\"{u}r FIGO I Ovarialkarzinome evaluieren.



Methoden Die Therapiequalit\"{a}t orientierte sich an g\"{u}ltigen Therapiestandards und Leitlinien. OP-Qualit\"{a}t wurde als „optimal“ (OP+: maximal 1 OP-Parameter fehlend), vs. „suboptimal“ (OP-) kategorisiert.



Ergebnisse 19,9% (n=700) hatten ein FIGO I OC. Medianes Follow-up betrug 51,0 Monate. Medianes Alter war 60 Jahre. 40,1% waren ≥65 Jahre, 47,1% mit FIGO IA, 47,9% FIGO IC. 37,1% waren high-grade ser\"{o}s. Die OP-Qualit\"{a}t nahm im Verlauf zu. Der operative Standard erh\"{o}hte sich im Beobachtungszeitraum von 19,9% auf 54,1%. Das OP+ Kollektiv stieg von 42,2% auf 70,9%. Das progressionfreie Survival (PFS) war signifikant verbessert bei OP+ (84% nach 48 Monaten im Vergleich zu 71% bei nicht optimaler Operation). Ebenso war das Gesamt\"{u}berleben (OS) signifikant verl\"{a}ngert mit 91% nach 48 Monaten bei OP+ vs. 76% bei OP-. 20,7% wurden systemtherapeutisch untertherapiert, 1,0% \"{u}bertherapiert. Der optimale Chemotherapiestandard (CT+) wurde zunehmend h\"{a}ufiger verabreicht (71,4% auf 80,8%). PFS und OS waren signifikant verl\"{a}ngert bei CT+. Die OP+/CT+ Subgruppe stieg im Verlauf von 37,9% auf 54,1% und war mit signifikant verl\"{a}ngertem PFS und OS assoziiert (OS (48 Monate): OP+/CT+ 93%, OP-/CT+ 68%).



Zusammenfassung Zwar geht aus den retrospektiven QS-Ovar-Daten hervor, dass sich die Therapiequalit\"{a}t im Laufe der Jahre stetig verbessert hat, allerdings wurden bei fast 50% immer noch nicht alle operativen Standards eingehalten. Die kontinuierliche Erh\"{o}hung des OP+/CT+ Kollektivs ist somit ein wichtiges Instrument zur Verbesserung der Prognose von Ovarialkarzinompatientinnen.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{nokey,

title = {Qualit\"{a}tssicherung zum An\"{a}miemanagement bei Patientinnen und Patienten mit soliden Tumoren und h\"{a}matologischen Neoplasien (V808)},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann},

url = {https://www.karger.com/Article/Pdf/526456},

doi = {10.1159/000526456},

year  = {2022},

date = {2022-10-10},

urldate = {2022-10-10},

journal = {Oncology Research and Treatment},

volume = {45},

issue = {suppl 2},

pages = {251},

abstract = {Introduction: 

Anemia is a frequent complication in patients with breast cancer (BC), gastrointestinal tumors (GC), lung cancer (LC) and malignant lymphomas (ML). Guidelines (GL) on anemia management (ESMO; DGHO) provide dedicated algorithms for diagnosis and treatment of anemia. Aim of the study was to analyze GL adherence (GLAD) in Germany. 

Methods: 

This was a retrospective sample analysis representative for practices and hospitals in Germany. Data on tumor treatments and anemia management was collected from records of cancer patients (pts) with grade ≥ 2 anemia diagnosed between January and June 2021. Definition of diagnosis GLAD score (GLAD-D): 2 points (pt) for full adherence, 1 pt for a lack in differential diagnosis on iron metabolism. 0 pt if differential diag- nosis is missing. Treatment GLAD score (GLAD-T): 2 pt for full adherence to GL recommendation in relation to diagnosis. 1 pt for indicated red blood cells (RBC) as only anemia therapy or no therapy in pts with Hb ≥8g/dl. 0 pt for RBC without indication, p.o. iron substitution under inflammatory conditions (CRP\>5mg/l) or vitamin B12 or folate deficiency without substitution. Results: Data from 1046 pts (311 BC, 371 GC, 260 LC, 104 ML) were collected from 143 centers. 996 (92.4%) pts were treated with medical tumor therapy and 317 (30.3%) received radiotherapy. Hb-values at diagnosis of anemia were 8-10 g/dl in 899 (85.9%) pts, 6-8g/dl in 135 (12.9%) and \<6g/dl (1.2%) in 12 pts. 456 pts were treated with RBC (43.6%), 198 (18.9%) with iron substitution, 106 (10.1%) with ESA and 60 (5.7%) with vitamin B12. 60.6% of the pts with iron substitution were treated i.v. and 39.4% p.o. 37.5% of pts with RBC had no indication in the sense of the restrictive RBC policy recommended by the GLs.

GLAD was poor in diagnosis and treatment: GLAD-D was 2 pt in 310 pts (29.6%) of pts, 1 pt at 168 (16.1%) and 0 pt in 568 (54.3%) pts. GLAD-T was 2 pt in 270 pts (25.8%), 1 pt in 310 (29.6%) and 0 pt in 466 (44.6%).

Higher GLAD-D correlated significantly to a higher GLAD-T (τB 0.262, p\<0.001). Full GLAD-T (2 pt) was significantly associated with a greater Hb increase than GLAD-T 0/1 (p\<0.001) at 28 days (10.2 vs. 9.7 g/dl) and at 2 months (10.4 vs 9.9 g/dl).

Conclusions

Pts with anemia management as per GL had a significantly stronger Hb-increase. GLAD is poor in Germany, especially concerning the too liberal transfusion policy and the lack of differential diagnostics of iron metabolism.

NCT05190263},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN526,

title = {Qualit\"{a}tssicherung zur Therapie des muskelinvasiven und metastasierten Harnblasenkarzinoms in Deutschland},

author = {Carsten-Henning Ohlmann and Markus Kerkmann and Laura Holtmann and J\"{u}rgen E. Gschwend and Margitta Retz and Maike de Wit},

url = {https://doi.org/10.1007/s00120-022-01870-z},

doi = {10.1007/s00120-022-01870-z},

issn = {2731-7072},

year  = {2022},

date = {2022-06-29},

urldate = {2022-06-29},

journal = {Die Urologie},

volume = {61},

pages = {1351-1364},

abstract = {Background:

The S3-guideline on bladder cancer recommends radical cystectomy and cisplatin-based perioperative chemotherapy (POC) for muscle-invasive bladder cancer (MIBC). Recommendation for metastatic urothelial cancer (mUC) is cisplatin-based or immuno-oncological (IO) treatment in platinum-ineligible patients (pts) or as 2nd-line therapy.

Objectives:

Aim of the study was to obtain representative data on clinical routine treatment of MIBC and mUC in Germany.

Materials and methods:

A nationwide survey was performed to obtain data on stage-related patient volume in hospitals and office-based physicians. Based on these results, a representative sample of treatment data was collected retrospectively from pts with MIBC and mUC.

Results:

Data from 956 pts (MIBC 576; mUC: 380) were collected. Of the MIBC pts, 49.8% received a systemic therapy (80.4% of them received cisplatin/gemcitabine) and 50.2% were treated with a cystectomy without POC. Significant factors for cystectomy without POC were higher age \> 75 years (odds ratio [OR] 4.91, 95% confidence interval [CI] 3.01\textendash8.11, p \< 0.001) and platinum-ineligible pts (OR 2.15, 95% CI 1.30\textendash3.59; p = 0.003). Treatment decision without interdisciplinary tumor board was also correlated with no POC (OR 2.43, 95% CI 1.65\textendash3.61, p \< 0.001). In mUC platinum-pretreated pts generally receive IO therapy (OR 12.07, 95% CI 6.94\textendash21.82, p \< 0.001). Other significant factors are positive PD-L1 status (OR 3.72, 95% CI 1.30\textendash5.71, p \< 0.001), higher age \> 75 years (OR 2.83, 95% CI 1.43\textendash5.73, p = 0.003) and platinum-ineligible pts (OR 2.57, 95% CI 1.30\textendash5.71, p = 0.007).

Conclusions:

The “gold standard” cisplatin/gemcitabine is established in Germany if pts are treated with POC. Nonetheless half of the MIBC pts did not receive a POC, especially if the treatment decision is not discussed in a tumor board. In mUC IO therapy is established as 2nd-line therapy after a platinum-based treatment. Although the guideline recommendations are largely implemented, there is potential for optimization, especially in the establishment of interdisciplinary tumor boards.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN524,

title = {Immunoglobulin substitution in patients with secondary antibody deficiency in chronic lymphocytic leukemia and multiple myeloma: a representative analysis of guideline adherence and infections},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann and Working Groups Supportive Care (AGSMO), Medical Oncology (AIO) of the German Cancer Society (DKG)},

url = {https://doi.org/10.1007/s00520-022-06920-y},

doi = {10.1007/s00520-022-06920-y},

issn = {1433-7339},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Supportive Care in Cancer},

volume = {30},

number = {6},

pages = {5187-5200},

abstract = {Introduction

In secondary immunodeficiency, immunoglobulin replacement therapy (IgRT) is recommended by guidelines (GL) for patients with IgG level \< 4 g/l and more than 3 infections or a severe infection. IgRT may be appropriate if IgG level \< 4 g/l and/or 1\textendash3 less severe infections (≤ grade 2).

Methods

This was a retrospective sample analysis representative for practices and hospitals in Germany. The treatments and infection data were collected from patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). GL adherence (GLAD) was analyzed.

Results

Data from 1086 patients (CLL 490, MM 596) were collected from 86 centers. Of all patients, 34.8% developed IgG deficiency during therapy (CLL 35.5%; MM 34.2%). IgRT was given in 23.5% of CLL and 14.4% of MM patients. GLAD in hypogammaglobulinemia and indication to IgRT was 23.3% of 86 CLL and 22.1% of 77 MM patients. Without GLAD, the hazard ratio (HR) for any infection was 4.49 (95% CI 3.72\textendash5.42; p \< 0.001) and for severe infections (grade ≥ 3) 10.64 (95% CI 7.54\textendash15.00; p \< 0.001). Significant independent risk factors for infections were a higher Charlson Comorbidity Index, IgG deficiency, and 3rd + line treatment, as well as therapy with BTK inhibitors or chemotherapy in CLL. Multivariable analysis showed a significantly lower risk of severe infections after start of IgRT with a HR of 0.47 (95% CI 0.28\textendash0.77; p = 0.003).

Conclusions

Guideline adherence correlated with fewer and less severe infections but was low in patients with indication to IgRT. Risk factors for infection can be identified. Risk of severe infections was significantly lower in patients with IgRT.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN527,

title = {Treatment and outcome of patients with high-grade advanced ovarian cancer (AOC): Real-world data in Germany (QS Ovar of the AGO Study Group)},

author = {Sven Mahner and Philipp Harter and Andreas Du Bois and Felix Hilpert and Markus Kerkmann and Jalid Sehouli and Nikolaus Gregorio and Lars Ch Hanker and Florian Heitz and Frederik Marm\'{e} and Linn Lena Woelber and Laura Holtmann and Gabriele Elser and Jacobus Pfisterer},

url = {https://doi.org/10.1200/JCO.2022.40.16_suppl.e17613},

doi = {10.1200/JCO.2022.40.16_suppl.e17613},

issn = {0732-183X},

year  = {2022},

date = {2022-01-01},

urldate = {2022-01-01},

journal = {Journal of Clinical Oncology},

volume = {40},

number = {16_suppl},

pages = {e17613-e17613},

abstract = {Background: 

Outcome of patients with ovarian cancer depends largely on treatment quality and expertise of treating physicians and centers. To assess treatment reality and quality in Germany, we initiated a nationwide quality assurance program. 

Methods: 

All German hospitals treating patients with ovarian cancer were asked to document their patients with primary diagnosis of epithelial ovarian cancer in the third quarters of 2012 and 2016. Details of tumor, treatment and outcome were documented in a central database. The current analysis focuses on patients with high-grade AOC stage III/IV. 

Results: 

In total, 1010 patients with high-grade AOC were documented. This represents 63% of all patients diagnosed with AOC in Germany in these periods. Median age was 65 years. The majority (774/1010 - 76.6%) were diagnosed with stage III disease and 947/1010 (93.8%) had serous, 34 (3.4%) endometrioid and 29 (2.9%) clear cell histology. 915/1010 (90.6%) had primary cytoreductive surgery. Complete resection was achieved in 434/915 (47.4%) at primary surgery and in 54/95 (56.8%) at interval debulking surgery. Median PFS and OS in patients with primary surgery and complete resection was 29.7 months and 63.1 months compared to 16.8 months and 30.7 months in patients with residual disease (HR PFS 0.46 95% CI 0.22-0.54 HR OS: 0.38 95% CI 0.31-0.45). In patients with neoadjuvant chemotherapy and interval debulking, median PFS and OS were 24.3 and 50.7 months with complete resection, compared to 15.4 and 33.9 months with residual disease (HR PFS 0.61 95% CI 0.38-0.95 HR OS: 0.48 95% CI 0.28-0.83). First-line chemotherapy was carboplatin/paclitaxel (TC) in 919/1010 (91%) of the patients, 627 (62%) also received bevacizumab (TCB) and 544 of these (87%) also received maintenance therapy. Median PFS and OS in patients with TCB was 23.3 months and 46.2 months and 18.5 months and 39.0 months in patients treated with TC (p = 0.049: HR 0.85, 95% CI 0.72-1.00 and p = 0.012: HR 0.79, 95% CI 0.65-0.95). The rate of complete tumor resection at surgery as well as the use of bevacizumab increased between the two periods. 

Conclusions: 

Based on this representative cohort of patients with advanced ovarian cancer in Germany, the majority of patients is treated with primary surgery followed by carboplatin/paclitaxel and bevacizumab. Patient outcome regarding PFS and OS was best when complete tumor resection was achieved at primary surgery and patients received combination chemotherapy with maintenance treatment. },

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN478,

title = {An\"{a}mie \textendash Diagnostik und Therapie bei soliden Tumoren und malignen Lymphomen},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann},

url = {https://doi.org/10.1007/s12312-021-00948-7},

doi = {10.1007/s12312-021-00948-7},

issn = {2190-9784},

year  = {2021},

date = {2021-01-01},

urldate = {2021-01-01},

journal = {Forum},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{HarterA200,

title = {123 Real world data of treatment and outcome of patients with high grade AOC (advanced ovarian cancer) in Germany (QS Ovar)},

author = {Philipp Harter and Andreas Du Bois and Felix Hilpert and Markus Kerkmann and Jalid Sehouli and Sven Mahner and Nikolaus De Gregorio and Lars Hanker and Florian Heitz and Frederik Marm\'{e} and Linn W\"{o}lber and Laura Holtmann and Jacobus Pfisterer},

url = {https://ijgc.bmj.com/content/31/Suppl_3/A200.1},

doi = {10.1136/ijgc-2021-ESGO.342},

issn = {1048-891X},

year  = {2021},

date = {2021-01-01},

urldate = {2021-01-01},

journal = {International Journal of Gynecologic Cancer},

volume = {31},

number = {Suppl 3},

pages = {A200--A200},

publisher = {BMJ Specialist Journals},

abstract = {Introduction/Background*Recent and detailed data regarding treatment quality and outcome of patients with high grade AOC on a nationwide basis are largely unknown in Germany.Methodology All German hospitals treating patients with ovarian cancer were asked to document all patients with first diagnosis in the third quarter in 2012 and 2016. Details of tumor, treatment and outcome were documented. This analysis is focusing on patients with AOC FIGO III/IV and the endpoint PFS (progression free survival) (OS data immature for 2016 cohort). As response rates were not documented, we defined a subcohort of patients without progressive disease within 3 months after end of chemotherapy as potential candidates for an additional maintenance therapy.Result(s)*In total, 1010 patients with high grade AOC with a median age of 65 years were documented. 774/1010 (76.6%) were diagnosed with FIGO III disease and 947/1010 (93.8%) had high-grade serous histologic subtype. 915/1010 (90.6%) had primary cytoreductive surgery. Complete resection was achieved in 434/1010 (43.0%) at primary surgery and in 54/1010 (5.3%) at interval debulking surgery. Carboplatin/paclitaxel/bevacizumab (TCB) was the primary systemic therapy in 627/1010 (62.1%) and carboplatin/paclitaxel (TC) in 292/1010 (28.9%). Median PFS in patients with primary surgery and complete resection was 29.7 months (95% CI 27.4-34.2) compared to 17.2 months (95% CI 15.7-18.9) in all other patients (p\<0.001: HR 0.49, 95% CI 0.42-0.57). Median PFS in patients with TCB was 23.3 months (95% CI 22.0-25.3) and 18.5 months (95% CI 15.7-21.9) in patients treated with TC (p=0,083: HR 0.87, 95% CI 0.74-1.02). In total, 899/1010 (89%) did not progress within 3 months.Conclusion*Most patients in Germany with high grade AOC are treated with primary surgery followed by carboplatin/paclitaxel/bevacizumab. Depending on biomarker status most patients are potential candidates for a PARP-inhibitor maintenance therapy.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN66,

title = {Die Therapiequalit\"{a}t des fortgeschrittenen Ovarialkarzinoms in Deutschland},

author = {P. Harter and J. Pfisterer and F. Hilpert and J. Sehouli and C. Lamparter and M. Kerkmann and A. Bois},

url = {https://www.eierstock-krebs.de/wp-content/uploads/2020/04/FA-2020-03-DIAG_Harter.pdf},

year  = {2020},

date = {2020-01-01},

urldate = {2020-01-01},

journal = {Frauenarzt},

volume = {61},

number = {3},

pages = {182-188},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN480,

title = {Steigerung der Therapiequalit\"{a}t des Ovarialkarzinoms in Deutschland \textendash Ergebnisse der eigenverantwortlichen QS Ovar},

author = {F. Hilpert and A. Bois and J. Pfisterer and J. Sehouli and C. Lamparter and M. Kerkmann and P. Harter},

url = {http://dx.doi.org/10.1055/s-0040-1718217},

doi = {10.1055/s-0040-1718217},

issn = {0016-5751 DOI - 10.1055/s-0040-1718217},

year  = {2020},

date = {2020-01-01},

urldate = {2020-01-01},

journal = {Geburtshilfe Frauenheilkd},

volume = {80},

number = {10},

pages = {P389},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN466,

title = {Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany},

author = {Hartmut Link and Ingo Diel and Carsten- H. Ohlmann and Laura Holtmann and Markus Kerkmann and Medical Oncology Urological Oncology German Cancer Society Oncology and Society German Osteooncological},

url = {https://doi.org/10.1007/s00520-019-05018-2},

doi = {10.1007/s00520-019-05018-2},

issn = {1433-7339},

year  = {2020},

date = {2020-01-01},

urldate = {2020-01-01},

journal = {Supportive Care in Cancer},

volume = {28},

number = {5},

pages = {2175-2184},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN467,

title = {Quality assurance on diagnosis and therapy of secondary immunodeficiencies (SID) in patients with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) in Germany (QS-SID)},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann},

doi = {10.1159/000510995},

year  = {2020},

date = {2020-01-01},

urldate = {2020-01-01},

journal = {Oncology Research and Treatment},

volume = {43},

number = {Suppl. 4},

pages = {A280},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN537,

title = {QS ENDO Real - A Study by the German Endometriosis Research Foundation (SEF) on the Reality of Care for Patients with Endometriosis in Germany, Austria and Switzerland},

author = {F. Zeppernick and M. Zeppernick and E. Janschek and M. W\"{o}lfler and S. Bornemann and L. Holtmann and F. Oehmke and I. Brandes and C. M. Scheible and D. Salehin and S. V. Pethick and A. S. Boosz and B. Kr\"{a}mer and M. Sillem and K. B\"{u}hler and J. Keckstein and K. W. Schweppe and I. Meinhold-Heerlein},

doi = {10.1055/a-1068-9260},

issn = {0016-5751 (Print) 0016-5751},

year  = {2020},

date = {2020-01-01},

urldate = {2020-01-01},

journal = {Geburtshilfe Frauenheilkd},

volume = {80},

number = {2},

pages = {179-189},

abstract = {Endometriosis affects a significant number of young premenopausal women. Quite apart from the medical challenges, endometriosis is a relevant burden for healthcare and social security systems. Standardized quality indicators for the treatment of endometriosis have not previously been systematically verified. The three-stage study QS ENDO was initiated to record and improve the reality and quality of care. One of its aims is to create quality indicators for the diagnosis and treatment of endometriosis. For the first stage of QS ENDO Real, letters were sent to all 1014 gynecological departments in the German-speaking area of Europe (the DACH region) which included a questionnaire as a means of surveying the current state of care. A total of 296 (29.2%) of the centers which received the questionnaire participated in the survey. The subsequent evaluation of the completed questionnaires showed that the majority of patients with endometriosis (around 60%, based on estimates from the data) are not treated in hospitals which have been certified by the SEF. The guidelines recommend the use of specific classification systems (rASRM, ENZIAN) but, depending on the level of care offered by the hospital, only around 44.4 to 66.4% of departments used the rASRM score and only 27% of hospitals used the ENZIAN classification system to describe deep-infiltrating endometriosis. When taking patientsʼ medical history, some centers (6.6 \textendash 17.9%) considered questions about leading symptoms such as dyschezia, dysuria and dyspareunia to be unimportant. QS ENDO Real has made it possible, for the first time, to get an overview of the reality of care provided to patients with endometriosis in the German-speaking areas of Europe. The findings indicate that several of the measures recommended in international guidelines as the gold standard of care are only used to treat some of the patients. In this respect, more efforts will be needed to provide more advanced training. The approach used for treatment must be guideline-based, also in not-certified centers, to improve the quality of care in the treatment of patients with endometriosis.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN20,

title = {EP869 Treatment of ovarian cancer in Germany from 2004\textendash2016: results of a nationwide quality assurance program (QS Ovar)},

author = {P Harter and J Pfisterer and F Hilpert and J Sehouli and C Lamparter and M Kerkmann and A Bois},

url = {https://ijgc.bmj.com/content/ijgc/29/Suppl_4/A471.2.full.pdf},

doi = {10.1136/ijgc-2019-ESGO.917},

year  = {2019},

date = {2019-01-01},

journal = {International Journal of Gynecologic Cancer},

volume = {29},

number = {Suppl 4},

pages = {A471-A471},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN1,

title = {Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany},

author = {H Link and I Diel and C H Ohlmann and L Holtmann and Urological Oncology (AUO) Medical Oncology (AIO) M Kerkmann for the Associations Supportive Care in Oncology (AGSMO) and German Osteooncological Society (DOG)},

url = {https://www.ncbi.nlm.nih.gov/pubmed/31410600},

doi = {10.1007/s00520-019-05018-2},

issn = {1433-7339 (Electronic) 0941-4355 (Linking)},

year  = {2019},

date = {2019-01-01},

journal = {Support Care Cancer},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN19,

title = {Sekund\"{a}re Immundefekte im Zeitalter zielgerichteter Therapien},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann},

url = {https://doi.org/10.1007/s12312-019-00707-9},

doi = {10.1007/s12312-019-00707-9},

issn = {2190-9784},

year  = {2019},

date = {2019-01-01},

urldate = {2019-01-01},

journal = {Forum},

volume = {34},

number = {6},

pages = {561-562},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN21,

title = {Behandlungsqualit\"{a}t des Ovarialkarzinoms in Deutschland: Aktuelle Ergebnisse des Qualit\"{a}tssicherungsprogramms QS OVAR},

author = {S Mahner and A Bois and J Pfisterer and F Hilpert and J Sehouli and C Lamparter and M Kerkmann and P Harter},

doi = {10.1055/s-0039-1693901},

issn = {0016-5751},

year  = {2019},

date = {2019-01-01},

journal = {Geburtshilfe Frauenheilkd},

volume = {79},

number = {08},

pages = {PD45},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN486,

title = {G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey},

author = {Hartmut Link and Markus Kerkmann and Laura Holtmann and Petra Ortner and Care Working Groups Supportive and Society Medical Oncology German Cancer},

url = {https://doi.org/10.1007/s00520-018-4481-x},

doi = {10.1007/s00520-018-4481-x},

issn = {1433-7339},

year  = {2019},

date = {2019-01-01},

urldate = {2019-01-01},

journal = {Supportive Care in Cancer},

volume = {27},

number = {4},

pages = {1459-1469},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN528,

title = {Therapieadh\"{a}renz beim Mammakarzinom im fr\"{u}hen (EBC) und metastasierten Setting (MBC) in Deutschland. Analyse der Organkommission Mamma der AGO 2004 \textendash 2018},

author = {C. Jackisch and T. Decker and J. Schilling and S. Schmitz and W. Lichtenegger and A. Jaeger and S. Bornemann},

url = {https://doi.org/10.1055/s-0039-1687991},

doi = {10.1055/s-0039-1687991},

issn = {1611-6453 DOI - 10.1055/s-0039-1687991},

year  = {2019},

date = {2019-01-01},

urldate = {2019-01-01},

journal = {Senologie - Zeitschrift f\"{u}r Mammadiagnostik und -therapie},

volume = {16},

number = {02},

pages = {58},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN22,

title = {Therapy of ovarian cancer (OC) in Germany \textendash Treatment characteristics and survival results of the QS OVAR 2012},

author = {P Harter and A Bois and F Hilpert and J Rochon and C Lamparter and M Kerkmann and J Pfisterer},

doi = {10.1055/s-0038-1671031},

issn = {0016-5751},

year  = {2018},

date = {2018-01-01},

journal = {Geburtshilfe Frauenheilkd},

volume = {78},

number = {10},

pages = {P 120},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN23,

title = {Combination of conventional prognostic factors and molecular subtypes for selecting the timing of systemic therapy in early operable breast cancer.},

author = {Christian Jackisch and Andreas Jaeger and Sebastian Bornemann},

url = {https://www.karger.com/DOI/10.1159/000487109},

doi = {10.1159/000487109},

issn = {2296-5270},

year  = {2018},

date = {2018-01-01},

urldate = {2018-01-01},

journal = {Oncology Research and Treatment},

volume = {41(suppl 1)},

number = {ID 510},

pages = {1-221},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN27,

title = {QS Endo \textendash Eine Studie zur Versorgungsqualit\"{a}t von Endometriosepatientinnen in Deutschland, \"{O}sterreich und der Schweiz},

author = {M Zeppernick and F Zeppernick and I Meinhold-Heerlein},

doi = {10.1055/s-0038-1671384},

issn = {0016-5751},

year  = {2018},

date = {2018-01-01},

journal = {Geburtshilfe Frauenheilkd},

volume = {78},

number = {10},

pages = {P 220},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN414,

title = {Qualit\"{a}tssicherung Ovarialkarzinom in Deutschland - Erhebung 2016},

author = {P Harter and F Hilpert and J Pfisterer and J Sehouli and C Lamparter and M Kerkmann and A Du Bois},

doi = {10.1055/s-008-41512},

year  = {2018},

date = {2018-01-01},

urldate = {2018-01-01},

journal = {Geburtshilfe und Frauenheilkunde},

volume = {78},

number = {10},

pages = {94},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN415,

title = {Guideline adherence in bone targeted therapy of cancer patients with bone metastases in Germany},

author = {Hartmut Link and Ingo Diel and Carsten-Henning Ohlmann and Laura Holtmann and Markus Kerkmann},

url = {https://www.karger.com/Article/Pdf/479566#634},

issn = {2296-5270},

year  = {2017},

date = {2017-01-01},

urldate = {2017-01-01},

journal = {Oncology Research and Treatment},

volume = {40},

number = {Suppl 3},

pages = {P634},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN24,

title = {Timing der (neo)adjuvanten Systemtherapie beim Mammakarzinom in Deutschland in den Jahren 2004 bis 2014. Resultate der Erhebungen der Organkommission Mamma der AGO mit Unterst\"{u}tzung von AIO, BNGO, BNHO, NOGGO.},

author = {C Jackisch and U -S Albert and I Bauerfeind and J -U Blohmer and P Dall and V Heinemann and H -J Hindenburg and A Jaeger and C Lamparter and W Lichtenegger and H -J L\"{u}ck and G Minckwitz and V M\"{o}bus and U Nitz and S Schmitz and M Untch and A Scharl},

url = {https://www.karger.com/DOI/10.1159/000444354},

doi = {10.1159/000444354},

issn = {2296-5270},

year  = {2016},

date = {2016-01-01},

journal = {Oncology Research and Treatment},

volume = {39(suppl 1)},

number = {ID 0357},

pages = {1-191},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN3g,

title = {Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany},

author = {Hartmut Link and Josef Nietsch and Markus Kerkmann and Petra Ortner German Cancer Society (DKG)},

url = {https://www.ncbi.nlm.nih.gov/pubmed/26081593},

doi = {10.1007/s00520-015-2779-5},

issn = {1433-7339 (Electronic) 0941-4355 (Linking)},

year  = {2016},

date = {2016-01-01},

urldate = {2016-01-01},

journal = {Support Care Cancer},

volume = {24},

number = {1},

pages = {367-376},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN134,

title = {Implementation of G-CSF-guidelines to prevent febrile neutropenia after chemotherapy in patients with lung or breast cancer \textendash second representative sample survey in Germany},

author = {H. Link and L. Holtmann and M. Kerkmann and P. Ortner},

url = {http://www.karger.com/DOI/10.1159/000449050},

doi = {DOI:10.1159/000449050},

issn = {2296-5270},

year  = {2016},

date = {2016-01-01},

urldate = {2016-01-01},

journal = {Oncology Research and Treatment},

volume = {39},

number = {suppl 3},

pages = {1-348},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN25,

title = {Aktuelle Versorgungslage der chemotherapeutischen Versorgung von Patientinnen mit metastasiertem Mammakarzinom in Deutschland \textendash Eine Umfrage der Organkommission Mamma der AGO},

author = {C Jackisch and U Albert and I Bauerfeind and J Blohmer and P Dall and V Heinemann and H Hindenburg and A Jaeger and C Lamparter and W Lichtenegger and H L\"{u}ck and G Minckwitz and V M\"{o}bus and U Nitz and S Schmitz and M Untch and A Scharl},

doi = {10.1055/s-0035-1550508},

issn = {1611-6453},

year  = {2015},

date = {2015-01-01},

journal = {Senologie - Zeitschrift f\"{u}r Mammadiagnostik und -therapie},

volume = {12},

number = {02},

pages = {A68},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN35,

title = {Anwendung antiemetischer Leitlinien bei hoch emetogener Chemotherapie \textendash eine retrospektive repr\"{a}sentative Datenerhebung und Analyse in Deutschland},

author = {Hartmut Link and Josef Nietsch and Markus Kerkmann and Karin Jordan and Petra Ortner},

url = {https://www.karger.com/DOI/10.1159/000439070},

doi = {10.1159/000439070},

issn = {2296-5270},

year  = {2015},

date = {2015-01-01},

urldate = {2015-01-01},

journal = {Oncology Research and Treatment},

volume = {38(suppl 5)},

number = {Suppl. 5},

pages = {V629},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN132,

title = {Adherence to antiemetic guidelines for highly emetogenic chemotherapy \textendash a retrospective representative sample survey and analysis in Germany},

author = {H. Link and J. Nietsch and M. Kerkmann and K. Jordan and P. Ortner},

url = {http://www.karger.com/DOI/10.1159/000439070},

issn = {2296-5270},

year  = {2015},

date = {2015-01-01},

urldate = {2015-01-01},

journal = {Oncology Research and Treatment},

volume = {38},

number = {Suppl. 5},

pages = {192 V629},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN36,

title = {How oncologists adhere to evidence-based G-CSF-guidelines to prevent febrile neutropenia: A sample survey in hospitals and practices in Germany},

author = {Hartmut Link and Josef Nietsch and Markus Kerkmann and Petra Ortner},

url = {https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.6591},

doi = {10.1200/jco.2013.31.15_suppl.6591},

issn = {0732-183X},

year  = {2013},

date = {2013-01-01},

urldate = {2013-01-01},

journal = {Journal of Clinical Oncology},

volume = {31},

number = {15_suppl},

pages = {6591-6591},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN29,

title = {Clinical research in epithelial ovarian cancer and patients' outcome},

author = {J Rochon and A Bois},

url = {https://doi.org/10.1093/annonc/mdr421},

doi = {10.1093/annonc/mdr421},

issn = {0923-7534},

year  = {2011},

date = {2011-01-01},

journal = {Annals of Oncology},

volume = {22},

pages = {vii16-vii19},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN28,

title = {Eigenverantwortliche Qualit\"{a}tssicherung zur Therapiequalit\"{a}t des Ovarialkarzinoms in Deutschland},

author = {F Hilpert and P Harter and J Pfisterer and J Rochon and J Friedemann and C Lamparter and A Bois},

url = {https://doi.org/10.1007/s00129-010-2679-1},

doi = {10.1007/s00129-010-2679-1},

issn = {1433-0393},

year  = {2010},

date = {2010-01-01},

journal = {Der Gyn\"{a}kologe},

volume = {43},

number = {12},

pages = {1022-1027},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN26,

title = {Das Mammakarzinom: Versorgungslage und Therapiequalit\"{a}t in Deutschland 2004},

author = {C Jackisch and M Untch and D Chatsiproios and C Lamparter and F Overkamp and W Lichtenegger and W R\"{o}nsberg and C Thomssen and G Minckwitz},

doi = {10.1055/s-2006-955230},

issn = {0044-4197},

year  = {2006},

date = {2006-01-01},

journal = {Zentralbl Gynakol},

volume = {128},

number = {06},

pages = {352-361},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN32,

title = {Das Qualit\"{a}tssicherungsprogramm der AGO Organkommission OVAR (QS-OVAR): Versorgungsstruktur und Realit\"{a}t in Deutschland 2001},

author = {Andreas Bois and Justine Rochon and Christiane Lamparter and Jacobus Pfisterer},

doi = {10.1055/s-2005-836289},

issn = {0044-4197},

year  = {2005},

date = {2005-01-01},

urldate = {2005-01-01},

journal = {Zentralbl Gynakol},

volume = {127},

number = {01},

pages = {9-17},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{RN33,

title = {Welchen Einfluss haben Klinikmerkmale auf die Prognose beim Ovarialkarzinom in Deutschland?},

author = {Andreas Bois and Justine Rochon and Christiane Lamparter and Jacobus Pfisterer and AGO Organkommission Ovar},

doi = {10.1055/s-2005-836290},

issn = {0044-4197},

year  = {2005},

date = {2005-01-01},

urldate = {2005-01-01},

journal = {Zentralbl Gynakol},

volume = {127},

number = {01},

pages = {18-30},

keywords = {},

pubstate = {published},

tppubtype = {article}

}